212 related articles for article (PubMed ID: 34608628)
1. Long-term efficacy, tolerability, and retention of brivaracetam in epilepsy treatment: A longitudinal multicenter study with up to 5 years of follow-up.
Strzelczyk A; Zaveta C; von Podewils F; Möddel G; Langenbruch L; Kovac S; Mann C; Willems LM; Schulz J; Fiedler B; Kurlemann G; Schubert-Bast S; Rosenow F; Beuchat I
Epilepsia; 2021 Dec; 62(12):2994-3004. PubMed ID: 34608628
[TBL] [Abstract][Full Text] [Related]
2. Postmarketing experience with brivaracetam in the treatment of epilepsies: A multicenter cohort study from Germany.
Steinig I; von Podewils F; Möddel G; Bauer S; Klein KM; Paule E; Reif PS; Willems LM; Zöllner JP; Kunz R; Runge U; Kurlemann G; Schubert-Bast S; Rosenow F; Strzelczyk A
Epilepsia; 2017 Jul; 58(7):1208-1216. PubMed ID: 28480518
[TBL] [Abstract][Full Text] [Related]
3. Brivaracetam for the treatment of refractory epilepsy in patients with prior exposure to levetiracetam: A retrospective outcome analysis.
Snoeren A; Majoie MHJM; Fasen KCFM; Ijff DM
Seizure; 2022 Mar; 96():102-107. PubMed ID: 35184005
[TBL] [Abstract][Full Text] [Related]
4. BRIVEST: A 'real-world' observational, single-centre study investigating the efficacy, safety and tolerability of Brivaracetam.
Naddell S; Manuel M; Cavill R; White P; Sieradzan K
Epilepsy Behav; 2023 Jan; 138():108985. PubMed ID: 36442261
[TBL] [Abstract][Full Text] [Related]
5. Retention of brivaracetam in adults with drug-resistant epilepsy at a single tertiary care center.
Green SF; Hare N; Kassam M; Rugg-Gunn F; Koepp MJ; Sander JW; Rajakulendran S
Epilepsy Behav; 2022 Oct; 135():108868. PubMed ID: 35985166
[TBL] [Abstract][Full Text] [Related]
6. Tolerability, efficacy and retention rate of Brivaracetam in patients previously treated with Levetiracetam: A monocenter retrospective outcome analysis.
Hirsch M; Hintz M; Specht A; Schulze-Bonhage A
Seizure; 2018 Oct; 61():98-103. PubMed ID: 30118932
[TBL] [Abstract][Full Text] [Related]
7. Use of brivaracetam in genetic generalized epilepsies and for acute, intravenous treatment of absence status epilepticus.
Strzelczyk A; Kay L; Bauer S; Immisch I; Klein KM; Knake S; Kowski A; Kunz R; Kurlemann G; Langenbruch L; Möddel G; Müller-Schlüter K; Reif PS; Schubert-Bast S; Steinhoff BJ; Steinig I; Willems LM; von Podewils F; Rosenow F
Epilepsia; 2018 Aug; 59(8):1549-1556. PubMed ID: 29943451
[TBL] [Abstract][Full Text] [Related]
8. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents.
Schubert-Bast S; Willems LM; Kurlemann G; Knake S; Müller-Schlüter K; Rosenow F; Strzelczyk A
Epilepsy Behav; 2018 Dec; 89():89-93. PubMed ID: 30390435
[TBL] [Abstract][Full Text] [Related]
9. Adjunctive brivaracetam in focal and generalized epilepsies: A single-center open-label prospective study in patients with psychiatric comorbidities and intellectual disability.
Foo EC; Geldard J; Peacey C; Wright E; Eltayeb K; Maguire M
Epilepsy Behav; 2019 Oct; 99():106505. PubMed ID: 31493736
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, retention, and safety of brivaracetam in adult patients with genetic generalized epilepsy.
Fonseca E; Guzmán L; Quintana M; Abraira L; Santamarina E; Salas-Puig X; Toledo M
Epilepsy Behav; 2020 Jan; 102():106657. PubMed ID: 31731108
[TBL] [Abstract][Full Text] [Related]
11. Brivaracetam efficacy and tolerability in clinical practice: A UK-based retrospective multicenter service evaluation.
Adewusi J; Burness C; Ellawela S; Emsley H; Hughes R; Lawthom C; Maguire M; McLean B; Mohanraj R; Oto M; Singhal S; Reuber M
Epilepsy Behav; 2020 May; 106():106967. PubMed ID: 32179501
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and tolerability of adjunctive brivaracetam in adults with focal to bilateral tonic-clonic (secondary generalized) seizures: Post hoc pooled analysis.
Moseley BD; Dimova S; Elmoufti S; Laloyaux C; Asadi-Pooya AA
Epilepsy Res; 2021 Oct; 176():106694. PubMed ID: 34218211
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
Ben-Menachem E; Baulac M; Hong SB; Cleveland JM; Reichel C; Schulz AL; Wagener G; Brandt C
Epilepsy Res; 2021 Feb; 170():106526. PubMed ID: 33461041
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, tolerability and pharmacokinetic variability of brivaracetam in adults with difficult-to-treat epilepsy.
Svendsen T; Brodtkorb E; Linge HL; Burns ML; Johannessen SI; Nakken KO; Lossius MI; Landmark CJ
Epilepsy Res; 2022 Jul; 183():106946. PubMed ID: 35609355
[TBL] [Abstract][Full Text] [Related]
15. Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST).
Lattanzi S; Canafoglia L; Canevini MP; Casciato S; Chiesa V; Dainese F; De Maria G; Didato G; Falcicchio G; Fanella M; Ferlazzo E; Fisco G; Gangitano M; Giallonardo AT; Giorgi FS; La Neve A; Mecarelli O; Montalenti E; Piazza F; Pulitano P; Quarato PP; Ranzato F; Rosati E; Tassi L; Di Bonaventura C;
CNS Drugs; 2021 Dec; 35(12):1289-1301. PubMed ID: 34476770
[TBL] [Abstract][Full Text] [Related]
16. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy-A monocenter survey.
Steinhoff BJ; Bacher M; Bucurenciu I; Hillenbrand B; Intravooth T; Kornmeier R; Kurth C; Stockinger J; Staack AM
Seizure; 2017 May; 48():11-14. PubMed ID: 28364655
[TBL] [Abstract][Full Text] [Related]
17. Retention, efficacy, tolerability, and quality of life during long-term adjunctive brivaracetam treatment by number of lifetime antiseizure medications: A post hoc analysis of phase 3 trials in adults with focal seizures.
Brandt C; Dimova S; Elmoufti S; Laloyaux C; Nondonfaz X; Klein P
Epilepsy Behav; 2023 Jan; 138():108967. PubMed ID: 36435010
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a real-world, observational, retrospective study.
Liguori C; Manfredi N; Renna R; Izzi F; Pagliuca M; Pagliuca F; Mercuri NB; Fabio P
Epileptic Disord; 2020 Jun; 22(3):309-316. PubMed ID: 32540833
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of adjunctive brivaracetam in pediatric patients with epilepsy: An open-label, follow-up trial.
Lagae L; Klotz KA; Fogarasi A; Floricel F; Reichel C; Elshoff JP; Fleyshman S; Kang H
Epilepsia; 2023 Nov; 64(11):2934-2946. PubMed ID: 37597326
[TBL] [Abstract][Full Text] [Related]
20. Narrative Review of Brivaracetam: Preclinical Profile and Clinical Benefits in the Treatment of Patients with Epilepsy.
Klein P; Bourikas D
Adv Ther; 2024 Jul; 41(7):2682-2699. PubMed ID: 38811492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
